341 results about "Lung fibrosis" patented technology

Devices, systems and methods are disclosed for the formation of an arteriovenous fistula. Embodiments include catheter apparatus including an ablation element for creating and/or modifying the fistula. The devices, systems and methods can be used to treat patients with one or more numerous ailments including chronic obstructive pulmonary disease, congestive heart failure, hypertension, hypotension, respiratory failure, pulmonary arterial hypertension, lung fibrosis and adult respiratory distress syndrome.

A pharmaceutical composition and formulations comprise preventative, prophylactic or therapeutic amounts of an oligo(s) anti-sense to a specific gene(s) or its corresponding mRNA(s), and a glucocorticoid and/or non-glucocorticoid steroid or a ubiquinone or their salts. The agents, composition and formulations are used for treatment of ailments associated with impaired respiration, bronchoconstriction, lung allergy(ies) or inflammation, and abnormal levels of adenosine, adenosine receptors, sensitivity to adenosine, lung surfactant and ubiquinone, such as pulmonary fibrosis, vasoconstriction, inflammation, allergies, allergic rhinitis, asthma, impeded respiration, lung pain, cystic fibrosis, bronchoconstriction, COPD, RDS, ARDS, cancer, and others. The present treatment is effectively administered by itself for conditions without known therapies, as a substitute for therapies exhibiting undesirable side effects, or in combination with other treatments, e.g. before, during and after other respiratory system therapies, radiation, chemotherapy, antibody therapy and surgery, among others. Each of the agents of this invention may be administered directly into the respiratory system so that they gain direct access to the lungs, or by other effective routes of administration. A kit comprises a delivery device, the agents and instructions for its use.

The present invention is directed to methods for treating fibrosis conditions, such as liver, kidney and lung fibrosis, as well as fibrosis conditions of other tissues of the body. The methods of the invention comprise administering to a patient in need of such treatment a therapeutically effective amount of a B-cell antagonist. Exemplary B-cell antagonists that can be used in the practice of the methods of the invention include antibodies against B-cell surface antigens (e.g., antibodies against CD20), and BAFF antagonists.

A method and apparatus for determining the progressive potential of a disease is disclosed. The forward to backward propagating second harmonic generation signal derived from a second harmonic generation instrument is used to assess the collagen microstructure of imaged body tissue by way of numerical values that are in turn used to determine the progressive or metastatic potential of the disease. The disease may, for example, be a cancer such as breast cancer, lung fibrosis, colorectal adenocarcinoma, or the like. The apparatus may include in vivo instruments or laboratory diagnostic instruments with methods disclosed herein.

Disclosed are a human antibody comprising a human complementarity-determining region (CDR), which binds specifically to c-Met, and a framework region (FR), a polynucleotide encoding the human antibody, an expression vector comprising the polynucleotide, a transformant transformed with the expression vector, a method of producing the human antibody B7 by culturing the transformant, a wound healing composition comprising the human antibody as an active ingredient, a cell regeneration composition comprising the antibody as an active ingredient, and a drug conjugate comprising a drug linked to the human antibody. The c-Met-specific human antibody can function as an HGF mimic that can be used as a wound healing composition. The antibody can be widely used to determine the treatment and prognosis of various diseases, including neuronal infarction, progressive nephropathy, liver cirrhosis, lung fibrosis, kidney injury, liver injury, lung injury, and ulcerative wounds, which are treated by activation of HGF or c-Met.

Devices, systems and methods are disclosed for the formation of an arteriovenous fistula in the limb of the patient. Embodiments include an apparatus for the creation, modification and maintenance of a fistula, including the modification of an existing dialysis fistula; and a method of supplying oxygenated blood to the venous circulation of a patient. A kit of anastomotic implants is described which supports a broad base of patient anatomies and fistula locations. The devices, systems and methods can be used to treat patients with one or more numerous ailments including chronic obstructive pulmonary disease, congestive heart failure, hypertension, hypotension, respiratory failure, pulmonary arterial hypertension, lung fibrosis and adult respiratory distress syndrome.

The invention discloses a multifunctional fusion polypeptide and a preparation method and application thereof, and belongs to the field of biological pharmacy. The fusion polypeptide has the structural domains of Pro-(D-Pyr)-(D-Cys)-Bip-Arg-Gly-Glu, Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro, Arg-Gly-Asp and Gly-Gly-Gly-Gly; the fusion polypeptide can treat human lung fibrosis, pathological changes of lung tissue, lung cancers and other tumors, and in a lung fibrosis cell model, the fusion polypeptide can significantly reduce the hydroxyproline content in model group cells and inhibit the process of lung fibrosis. It is shown through MTT tests that the fusion polypeptide can inhibit proliferation of multiple kinds of anthropogenic tumor cells; the fusion polypeptide is prepared through an artificial synthesizing method, the preparation method is simple, and a good application prospect is achieved.

The invention provides a cutting machine with a dust collecting function and relates to the technical field of railways. The cutting machine with the dust collecting function comprises a cutting machine worktable. An L-shaped supporting frame is fixedly connected to the right side of the cutting machine worktable through a screw. A first motor bin is fixedly connected to the top of the L-shaped supporting frame. The top of the L-shaped supporting frame is located in a first motor bin and is fixedly connected with a first motor, and the output end of the first motor is fixedly connected with a first rotating shaft. The cutting machine with the dust collecting function is provided with an air outlet, the first motor, fan blades, a filtering net, a dust collecting box and a dust collecting pipe so that the cutting machine can have a dust collecting function, and the problems that most of current cutting machines need to be used for cutting through manual work, multiple metal particles can be mixed in air in the cutting process, the body is likely to be injured when workers inhale metal particles for a long time, and even irreversible diseases such as lung fibrosis and lung cancer are caused are effectively solved.

Relating to the fields of biotechnologies and gene therapy, the invention provides application of a gene modified mesenchymal stem cell in pulmonary fibrosis treatment. The gene modified mesenchymal stem cells are obtained through: in-vitro isolated culture and amplification of a mesenchymal stem cell (MSC) deriving from bone marrow and an umbilical cord, and recombinant adenovirus Ad-HGF mediated in-vitro modification of the MSC by a hepatocyte growth factor (HGF). By transplanting the gene modified MSC to a C57 mouse to intervene in radiation induced lung injury and fibrosis, exudation of a plurality proteins including albumin, IgM and the like from an alveolar space can be reduced, local inflammatory responses of the lung can be alleviated, and expression of TNF-alpha, soluble ICAM-1 and multiple factors is inhibited, expression of the profibrotic factor TGF-beta, the collagen gene col1 alpha 1 and col 3 alpha 1 can be inhibited, and pulmonary tissue collagen fiber deposition is reduced. The expression results of endogenous HGF and its receptor cmet show that endogenous HGF expression can be induced and endogenous MSC can home to injured parts. Therefore, the employment of HGF modified MSC in treatment of lung injury and fibrosis brought by various pathogenic causes is of great significance.

Disclosed herein are methods, constructs, kits, and the like, which can be used for detecting and/or differentiating interstitial lung disease. For example, idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP) can be detected and/or differentiated using at least one biomarker.

A COVID-19 Symptoms Alert Machine (CSAM) scanner, or apparatus, is described herein. This apparatus employs Artificial Intelligent (AI) technology in combination with the latest mobile device technology (viz. smart phone/smart watch) to quickly help track down people who have COVID-19 symptoms anywhere and anytime, isolate them, and professionally handle them, not allowing SARS-CoV-2 virus to spread. CSAM automatically measures body temperature and assesses lung conditions such as pulmonary fibrosis and B-lines (for asymptomatic people), and other current health vital information (CHVI), furnished by the participant, such as fever, sore throat, headache, and body ache to generate an alert signal when COVID-19 symptoms are found significant and to send it out to a COVID-19 control center. The alerted participant is then immediately required to go to the COVID-19 control center or be picked up by a special COVID-19 emergency vehicle for isolation and further evaluation and testing. If the testing turns out to be COVID-19 positive, the participant will be quarantined and treated appropriately according to COVID-19 protocol until he/she is tested COVID-19 negative. In the meantime, people who have been in close physical contact with this participant will be alerted and requested to be immediately checked for COVID-19 symptoms. If anyone is found to have COVID-19 symptoms, then he/she must go through the same protocol. The process is repeated until all people in the cluster are tested COVID-19 negative. This will ensure that SARS-CoV-2 virus for this cluster has been completely eliminated. A rapid deployment of this type of apparatus throughout communities where people tend to congregate such as superstores, supermarkets, and any other establishments, small or large, can help to contain the rapid spread of the disease, as well as to give more confidence to the general public. People, who pass through this apparatus without an alert signal, should feel more confident in carrying out their activities, though social distancing and other COVID-19 precautionary requirements should still be maintained. The concept can be further expanded to cover shopping malls, concert halls, sports arenas, and any other large events including highways and freeways with the help of mobile phone technologies, transponders, and other mobile devices. By working on the 0.6% (around 2 million infected people in the US as of June 2020) quickly and effectively, instead of on the 99.4% (330 million, the remaining population) by locking people at home and closing down all businesses and activities; we can save a significant amount of money and hassles. (A long lockdown can also lead to a collapse of our economy and can consequently lead to a worldwide calamity.) In this way the 99.4% will not be burdened with the virus problem and can live normally without having to take any test. It is probably the only effective approach in solving the COVID-19 problem at the moment because vaccines and known COVID-19 cures are not yet available. Even if SARS-CoV-2 vaccines are available presently, they may not be practical to implement economically and operationally in time to contain the virus worldwide due to the massive amount of people (viz. over 7 billion).

The present invention relates to novel interferon gamma polypeptide variants having interferon gamma (IFNG) activity, methods for their preparation, pharmaceutical compositions comprising the polypeptide variants and their use in the treatment of diseases, in particular for the treatment of interstitial pulmonary diseases, such as idiopathic pulmonary fibrosis. These novel polypeptide variants all comprise the substitution S99T as compared to the amino acid sequence of huIFNG or fragments thereof. By performing this mutation the naturally occurring N-glycosylation site present at position 97 is significantly better utilized. Preferably, the variants comprise further modifications, e.g. in order to increase the AUC of such variants when administered subcutaneously.

The invention discloses application of a mesenchymal stem cell exosome to preparation of a medicament for preventing and treating radiation-induced lung injury (RILI). After a radiated mouse with lunginjury is treated by adopting tail vein injection administration of the mesenchymal stem cell exosome, inflammatory factor level is effectively lowered (IL-1beta, IL-6, TNF-alpha, TGF-beta); the survival rate of the mouse is improved effectively; and pneumonia and lung fibrosis lesion caused by the RILI are reduced. The mesenchymal stem cell exosome has the advantages of high security, stable chemical property and easiness in storage, and a new way is provided for safely and effectively treating the RILI.

The invention belongs to the field of a health care product, and in particular relates to a complex vitamin and amino acid oral liquid as well as a preparation method and application thereof. The complex vitamin and amino acid oral liquid provided by the invention mainly consists of isoleucine, threonine, valine, aspartic acid, arginine hydrochloride, lysine hydrochloride, phenylalanine, methionine, leucine, tryptophan, nicotinamide, vitamin B1, vitamin B2, vitamin B6 and water. The complex vitamin and amino acid oral liquid provided by the invention is reasonable in compatibility of various components, and is capable of effectively keeping nutrient balance in human bodies; and meanwhile, the oral liquid also has functions of boosting immunity of organism and relieving fatigue of the human bodies. At the same time, upon tests, the complex vitamin and amino acid oral liquid has a certain effect on improving idiopathic pulmonary fibrosis.

The present invention relates to a gene specific siRNA related with respiratory diseases, particularly, to a gene specific siRNA related with idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease (COPD), and a highly efficient double-helical oligo RNA structure containing the same, wherein the double-helical oligo RNA structure has a structure in which hydrophilic and hydrophobic materials are bonded at the both ends of the double-helical RNA (siRNA) using a simple covalent bond or a linker-mediated covalent bond to be effectively transferred into a cell, and may be converted into nanoparticles by the hydrophobic interaction of the double-helical oligo RNA structure in a solution. It is desirable that the siRNA contained in the double-helical oligo RNA structure is a siRNA specific to a CTGF, Cyr61, or Plekho1, which are genes related with respiratory diseases, particularly idiopathic pulmonary fibrosis and COPD. In addition, the present invention relates to a method for producing the double-helical oligo RNA structure and a pharmaceutical composition containing the double-helical oligo RNA structure for preventing or treating respiratory diseases, particularly idiopathic pulmonary fibrosis and COPD.

The invention relates to an application of an isoalantolactone derivative and a salt thereof in the preparation of medicines for treating lung fibration, and provides an isoalantolactone derivative represented by formula (I). An acid for forming the salt is an inorganic acid or an organic acid, the inorganic acid is selected from hydrofluoric acid, hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, carbonic acid, boric acid, seleninic acid, phosphomolybdic acid, phosphorous acid and sulfurous acid, and the organic acid is selected from citric acid, maleic acid, D-malic acid, L-malic acid, DL-malic acid, L-lactic acid, D-lactic acid, DL-lactic acid, oxalic acid, methanesulfonic acid, pentanoic acid, oleic acid, lauric acid, p-methyl benzenesulfonic acid, 1-naphthalenesulfonic acid, 2-naphthalenesulfonic acid, phthalic acid, tartaric acid, propane diacid, succinic acid, fumaric acid, glycollic acid, thioglycollic acid, glycine, sarcosine, sulfonic acid, nicotinic acid, methylpyridine acid, isonicotinic acid, benzoic acid and substituted benzoic acid.

In fibrotic lung fibroblasts, basal levels of p53 protein (and miR-34a) are markedly suppressed, leading to reduced p53-mediated inhibition of uPA and uPAR, or concurrent induction of PAI-1. These changes contribute to excessive FL-fibroblast proliferation and production of extracellular matrix (ECM), and, therefore, pulmonary fibrosis. These processes are reversed by treating the cells, and treating subjects suffering from idiopathic pulmonary fibrosis (IPF) with the small organic molecule nutlin-3a (NTL) or with a peptide, CSP-4 (SEQ ID NO:1), or variants or derivatives or multimers of this peptide, which increase p53 levels by inhibiting MDM2-mediated degradation of p53 protein. Use of these compounds serves as a new approach to the treatment of IPF, they restore p53 expression and p53-mediated changes in the uPA-fibrinolytic system in FL-fibroblasts and restrict production and deposition of ECM.